OnKure Therapeutics, Inc. (OKUR)
NASDAQ: OKUR · Real-Time Price · USD
17.03
-0.15 (-0.87%)
Oct 25, 2024, 4:00 PM EDT - Market closed
Company Description
OnKure, Inc. engages in the discovery and development of oncology-precision medicines for the treatment of cancer.
The company focuses on developing selective inhibitors of histone deacetylases. Its portfolio includes OKI-179, an inhibitor for the treatment of both hematological and solid tumors.
The company was incorporated in 2011 and is based in Boulder, Colorado.
OnKure Therapeutics, Inc.
Country | United States |
Founded | 2011 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Nicholas Saccomano |
Contact Details
Address: 6707 Winchester Circle, Suite 400 Boulder, Colorado 80301 United States | |
Phone | 720 307 2892 |
Website | onkuretherapeutics.com |
Stock Details
Ticker Symbol | OKUR |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001637715 |
ISIN Number | US68277Q1058 |
Employer ID | 47-2309515 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Anthony D. Piscopio Ph.D. | Co-Founder, President, Chief Executive Officer and Director |
Jason A. Leverone CPA | Chief Financial Officer |
Dr. Dylan Hartley Ph.D. | Chief Scientific Officer |
Rogan P. Nunn | General Counsel and Secretary |
Prof. Xuedong Liu Ph.D. | Member of Scientific Advisory Board |
Dr. James Blake Ph.D. | Senior Vice President of Computational Drug Discovery |
Dr. Richard Woessner Ph.D. | Senior Vice President of Pharmacology |
Dr. Duncan Walker Ph.D. | Chief Development Officer |
Dr. Kevin S. Litwiler Ph.D. | Senior Vice President of DMPK and Clinical Pharmacology |
Dr. Samuel Agresta M.D., M.P.H. | Chief Medical Officer |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Oct 23, 2024 | S-1 | General form for registration of securities under the Securities Act of 1933 |
Oct 23, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Oct 21, 2024 | D | Notice of Exempt Offering of Securities |
Oct 16, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Oct 11, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
Oct 11, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
Oct 11, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
Oct 11, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
Oct 10, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
Oct 10, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |